Tempus AI (TEM) announced a record Total Contract Value, TCV, of more than $1.1 billion as of December 31, 2025. During 2025, Tempus signed data agreements with over 70 customers, spanning both large and mid-sized pharma as an increasing number of biopharma companies are incorporating Tempus’ “unique, multimodal dataset into their drug discovery and development efforts,” the company said.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Tempus AI price target lowered to $76 from $88 at TD Cowen
- TEM, KDK, PSNL: Cathie Wood Loads Up on AI Health Tech, Trims SHOP & ROKU
- Cathie Wood’s ARK Funds Had ‘One Heck of a Year’ — What’s Next for 2026?
- Tempus AI price target lowered to $80 from $95 at Canaccord
- Balanced Outlook on Tempus AI: Evaluating Data Business Expansion and Personalized Medicine Potential